Disappearance of factor VIII autoantibodies preceding autoimmune haemolytic anaemia

We describe a previously healthy woman who at the age of 44 years developed a factor VIII inhibitor, that over the years increased to a maximum level of 3600 Bethesda units (BU) mL–1 in 1978. The epitope specificity of the factor VIII inhibitor was investigated and antibodies directed against the A2 and C2 domains of factor VIII were detected. The majority of these antibodies were of subclass IgG4. Over the years, the inhibitor titre gradually decreased and in 1989, the inhibitor could no longer be detected. Shortly after, the patient developed autoimmune haemolytic anaemia. A possible link between the disappearance of factor VIII inhibitors and the development of other autoantibodies may be explained by concomitant development of anti‐idiotypic antibodies that neutralize the activity of factor VIII inhibitors. We were unable to detect anti‐idiotypic antibodies, which could explain the decline in factor VIII inhibitor titre in this patient.

[1]  J. T. ten Cate,et al.  A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. , 1998, Blood.

[2]  J. Banchereau,et al.  Memory B Cells Are Biased Towards Terminal Differentiation: A Strategy That May Prevent Repertoire Freezing , 1997, The Journal of experimental medicine.

[3]  I. Scharrer,et al.  The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. , 1997, Blood.

[4]  K. Rajewsky Clonal selection and learning in the antibody system , 1996, Nature.

[5]  J. Vermylen,et al.  Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. , 1996, The Journal of clinical investigation.

[6]  C. Kessler,et al.  Acquired inhibitors. , 1996, Bailliere's clinical haematology.

[7]  C. Kessler,et al.  A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. , 1995, Blood.

[8]  M. Kazatchkine,et al.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[9]  I. Maclennan,et al.  Distinct short‐lived and long‐lived antibody‐producing cell populations , 1986, European journal of immunology.

[10]  M. Kazatchkine,et al.  ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN , 1984, The Lancet.

[11]  K. Lechner,et al.  A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII , 1981, Thrombosis and Haemostasis.